Thymidine Kinase 2 Deficiency Tk2d — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for thymidine kinase 2 deficiency tk2d . 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2036. Daily refresh.

1
Approved drugs
2
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Thymidine Kinase 2 Deficiency Tk2d

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Ucb Inc 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating thymidine kinase 2 deficiency tk2d . Each bar = one year. Y-axis scaled to peak year (1 patents).

1
36
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Kygevvi
DOXECITINE
 Ucb Inc 2 75 — 2036-08-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10471087 Kygevvi method of use 75 2036-08-07
11649259 Kygevvi method of use 75 2040-08-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11649259 Kygevvi method of use 75 2040-08-19
10471087 Kygevvi method of use 75 2036-08-07

Related